Status:
COMPLETED
Liver Transplantation With ADV-TK Gene Therapy Improves Survival in Patients With Advanced Hepatocellular Carcinoma
Lead Sponsor:
Beijing Chao Yang Hospital
Collaborating Sponsors:
Tongji University
The No.180 Hospital of People's Liberation Army
Conditions:
Hepatocellular Carcinoma
Liver Transplantation
Eligibility:
All Genders
Phase:
PHASE2
Brief Summary
Previous rather poor results in liver transplantation (LT) of patients with advanced hepatocellular carcinoma (HCC) have made the application of LT very limited in treatment of HCC. The advantages of ...
Detailed Description
The overall survival in the LT with ADV-TK gene therapy group was 54.8 % at three years, and the recurrence-free survival in the same group was 56.5 %, both being higher than those in the transplantat...
Eligibility Criteria
Inclusion
- Clinical diagnosis of advanced hepatocellular carcinoma with no metastasis in lungs and bones
- Accept Liver Transplantation
Exclusion
- Small hepatocellular carcinoma
- Advanced hepatocellular with metastasis in lungs and bones
Key Trial Info
Start Date :
September 1 2000
Trial Type :
INTERVENTIONAL
End Date :
November 1 2005
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT00300521
Start Date
September 1 2000
End Date
November 1 2005
Last Update
March 9 2006
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Beijing Chao Yang Hospital
Beijing, Beijing Municipality, China, 100020